Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in obesity-related HFpEF
2019-004452-11Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Nov 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure with preserved ejection fraction (HFpEF) and obesity comparing Semaglutide 2.4 mg once weekly + standard of care with Placebo once weekly + standard of care (2 arms). Primary endpoint: Change in Kansas City Cardiomyopathy Questionnaire clinical summary score. Started Nov 2020; status: completed.
02
Drugs
03
Conditions
heart failure with preserved ejection fraction (HFpEF)obesity
Beyond the preview
Go deeper on 2019-004452-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004452-11.